Personalis, Inc. (PSNL)
NASDAQ: PSNL · Real-Time Price · USD
10.78
-0.36 (-3.23%)
At close: Jun 3, 2026, 4:00 PM EDT
10.77
-0.01 (-0.09%)
After-hours: Jun 3, 2026, 4:06 PM EDT
Personalis Employees
As of December 31, 2025, Personalis had 260 total employees, including 259 full-time and 1 part-time employees. The number of employees increased by 31 or 13.54% compared to the previous year.
Employees
260
Change (1Y)
31
Growth (1Y)
13.54%
Revenue / Employee
$248,135
Profits / Employee
-$367,508
Market Cap
1.13B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 260 | 31 | 13.54% | 259 | 1 |
| Dec 31, 2024 | 229 | 4 | 1.78% | 228 | 1 |
| Dec 31, 2023 | 225 | -174 | -43.61% | 223 | 2 |
| Dec 31, 2022 | 399 | 73 | 22.39% | 395 | 4 |
| Dec 31, 2021 | 326 | 91 | 38.72% | 325 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Myriad Genetics | 2,700 |
| NeoGenomics | 2,500 |
| OPKO Health | 2,275 |
| Fulgent Genetics | 1,315 |
| GeneDx Holdings | 1,300 |
| Castle Biosciences | 942 |
| GRAIL | 910 |
| CareDx | 765 |
PSNL News
- 1 day ago - Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026 - Business Wire
- 8 days ago - Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium - Business Wire
- 14 days ago - Personalis secures fourth Medicare coverage decision for NeXT Personal - TheFly
- 14 days ago - Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring - Business Wire
- 20 days ago - Personalis to Participate in Upcoming Investor Events - Business Wire
- 21 days ago - Personalis announces that CMS program expanded coverage for NeXT - TheFly
- 21 days ago - Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors - Business Wire
- 22 days ago - Personalis Transcript: AGM 2026 - Transcripts